Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

Inclusion Criteria: * Is able to provide written informed consent prior to study entry * Is male or female, 18 - 85 years of age * CLI with rest pain, tissue loss, or gangrene * No option for revascularization as a result of one of the following: * failed previous revascularization, such as recurrent instant restenosis or graft occlusion. * inadequate target vessels as determined by baseline CTA/angiogram at the time of enrollment. * or prohibitive medical comorbidities such as high risk cardiovascular or pulmonary disease which would restrict operative procedures * Final determination of no option for revascularization will be made by a vascular surgeon not associated with the clinical trial. * ABI less than 0.7, ankle pressure \< 50 mmHg, or toe pressure \< 30 mmHg. * TcPO2 \< 40 mmHg * SPP \< 35 mmHg * Female subjects must be of non childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy or hysterectomy\]) or must be using adequate contraception (practicing one of the following methods of birth control): * Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry), * A partner who is physically unable to impregnate the subject (e.g., vasectomized) * Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to patient's cell concentrate administration, * Intrauterine device (IUD), or * Double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream) * If female is of childbearing potential, subject must have a negative serum pregnancy test at screening * Confirmation of age-appropriate cancer screening consistent with the American Cancer Society guidelines Exclusion Criteria: * Patients with vascular lesions amenable to percutaneous intervention or where surgical bypass is indicated. * Any contraindication to stem cell or platelet-rich plasma therapy. * Isolated aorto-iliac stenoses or occlusions without infra-inguinal disease. * Pregnancy * Hemoglobin A1c \>10 % on day of enrollment. * Have an active malignancy or have undergone treatment for a malignancy in the preceding 5 years, with the exception of successful treatment of non-melanoma skin cancer. * Stage 4 or greater chronic kidney disease (eGFR \< 30 ml/min, MDRD estimate) * Hemoglobin \< 10 g/dl. * Thrombocytopenia \< 100,000 platelets/µL. * Unwilling or unable to comply with follow-up visits. * Proliferative retinopathy as determined by baseline retinal exam. * Is unable to refrain from nicotine, caffeine and alcohol for a period beginning 24 hours prior to the treatment visit * Has received an investigational medication or other study trial participation within 30 days prior to the Treatment Visit